Codexis, Inc.

CDXS Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of CDXS by members of U.S. Congress

Politician Type Traded
Lamar Smith House / R Purchase $1,001 - $15,000 Apr 06, 2018
CDXS Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CDXS Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CDXS Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in CDXS holdings by institutional investors

Insider Trading

Quarterly net insider trading by CDXS's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $10,000 Jan 18, 2013 Issue: Energy/Nuclear
  • $13,200 Oct 15, 2012 Issue: Chemicals/Chemical Industry
  • $5,244 Jul 19, 2012 Issue: Fuel/Gas/Oil Chemicals/Chemical Industry
  • $19,500 Apr 18, 2012 Issue: Science/Technology
  • $13,100 Oct 18, 2011 Issue: Fuel/Gas/Oil
  • $17,000 Jul 20, 2011 Issue: Fuel/Gas/Oil
  • $60,000 Jan 17, 2011 Issue: Energy/Nuclear
  • $60,000 Oct 19, 2010 Issue: Energy/Nuclear
  • $60,000 Jul 17, 2010 Issue: Energy/Nuclear
  • $60,000 Apr 18, 2010 Issue: Energy/Nuclear
  • $60,000 Jan 16, 2010 Issue: Energy/Nuclear
  • $80,000 Oct 19, 2009 Issue: Energy/Nuclear Environment/Superfund
  • $50,000 Jul 18, 2009 Issue: Energy/Nuclear Environment/Superfund
Corporate Lobbying

CDXS Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
Revenue Breakdown

CDXS Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CDXS Income Statement
CDXS Balance Sheet
CDXS Cash Flow
U.S. Patents

New CDXS patent grants

  • Patent Title: Polynucleotides encoding ketoreductase polypeptides for reduction of acetophenones Jan. 23, 2018
  • Patent Title: Ketoreductase polypeptides for the preparation of phenylephrine Dec. 05, 2017
  • Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Nov. 28, 2017
  • Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Nov. 21, 2017
  • Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Oct. 31, 2017
  • Patent Title: Biocatalysts for the preparation of hydroxy substituted carbamates Oct. 31, 2017
  • Patent Title: Ketoreductase polypeptides Oct. 24, 2017
  • Patent Title: Engineered proline hydroxylase polypeptides Oct. 17, 2017
  • Patent Title: Biocatalysts and methods for the synthesis of armodafinil Sep. 19, 2017
  • Patent Title: Pentose fermentation by a recombinant microorganism Sep. 05, 2017
  • Patent Title: Ketoreductase polypeptides for the production of azetidinone Aug. 01, 2017
  • Patent Title: Processes using amino acid dehydrogenases and ketoreductase-based cofactor regenerating system Jul. 25, 2017
  • Patent Title: Production of fatty alcohols from engineered microorganisms Jul. 25, 2017
  • Patent Title: Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs Jul. 18, 2017
  • Patent Title: P450-bm3 variants with improved activity Jul. 18, 2017
  • Patent Title: Polynucleotides encoding engineered imine reductases Jul. 04, 2017
  • Patent Title: Methods, systems, and software for identifying bio-molecules using models of multiplicative form Jun. 20, 2017
  • Patent Title: P450-bm3 variants with improved activity Jun. 20, 2017
  • Patent Title: Low-phosphate repressible promoter Jun. 06, 2017
  • Patent Title: Methods, systems, and software for identifying bio-molecules with interacting components May. 30, 2017
  • Patent Title: Engineered biocatalysts useful for carbapenem synthesis May. 30, 2017
  • Patent Title: Engineered ketoreductase polypeptides May. 23, 2017
  • Patent Title: Production of fatty alcohols from engineered microorganisms May. 16, 2017
  • Patent Title: Biocatalysts for ezetimibe synthesis May. 09, 2017
  • Patent Title: Synthesis of prazole compounds Apr. 25, 2017
  • Patent Title: Biocatalysts and methods for the synthesis of substituted lactams Apr. 18, 2017
  • Patent Title: Engineered transaminase polypeptides for industrial biocatalysis Apr. 11, 2017
  • Patent Title: Enone reductases Apr. 11, 2017
  • Patent Title: Pentose fermentation by a recombinant microorganism Apr. 04, 2017
  • Patent Title: Engineered phenylalanine ammonia lyase polypeptides Apr. 04, 2017
  • Patent Title: Endoglucanase 1b (eg1b) variants Apr. 04, 2017
  • Patent Title: Biocatalytic process for preparing eslicarbazepine and analogs thereof Mar. 28, 2017
  • Patent Title: Engineered tyrosine ammonia lyase Mar. 28, 2017
  • Patent Title: Protein variant generation by region shuffling Mar. 14, 2017
  • Patent Title: Ketoreductase polypeptides for the production of azetidinone Feb. 28, 2017
  • Patent Title: Transaminase biocatalysts Jan. 24, 2017
  • Patent Title: Variant lovd polypeptides and their uses Jan. 17, 2017
  • Patent Title: Engineered biocatalysts useful for carbapenem synthesis Jan. 10, 2017
  • Patent Title: Methods of using ketoreductase polypeptides for reduction of acetophenones Dec. 27, 2016
  • Patent Title: Fungal strains Dec. 27, 2016
  • Patent Title: Biocatalysts and methods for the synthesis of armodafinil Dec. 27, 2016
  • Patent Title: Modified native beta-ketoacyl-acp synthases and engineered microorganisms Dec. 06, 2016
  • Patent Title: Endoglucanase variants Dec. 06, 2016
  • Patent Title: Engineered transaminase polypeptides Dec. 06, 2016
  • Patent Title: Glucose and xylose co-utilization in Nov. 29, 2016
  • Patent Title: Use of glycohydrolase 61 protein variants with improved thermostability for processing cellulose Nov. 15, 2016
  • Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Nov. 08, 2016
  • Patent Title: Fungal beta-xylosidase variants Oct. 25, 2016
  • Patent Title: Ketoreductase polypeptides for the production of azetidinone Oct. 25, 2016
  • Patent Title: Variant endoglucanases and related polynucleotides Oct. 11, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to CDXS from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
CDXS News

Recent insights relating to CDXS

CNBC Recommendations

Recent picks made for CDXS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CDXS

CDXS Analyst Ratings

CDXS Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CDXS Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CDXS stock a Buy, Sell, or Hold?

  • What is the price target for $CDXS stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CDXS Top Shareholders
Shareholder
Shares Held
CDXS Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CDXS stock?

  • Who owns the most shares of $CDXS stock?

  • What funds own $CDXS stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CDXS Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CDXS Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CDXS

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

  • Address Redwood City, CA
  • Market Cap 139.1 million
  • Employees 188
  • Industrial Classification Industrial Organic Chemicals
Back To Top